SWShinji Watanabe

Shinji Watanabe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shinji Watanabe has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Hideki Hasegawa

    Research Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Tokyo 208-0011, Japan

    5 shared publications
  • Akihide Ryo

    Department of Microbiology, Yokohama City University School of Medicine, Yokohama, Japan; Department of Bioinformatics and Integrative Omics, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan

    2 shared publications
  • Atsushi Goto

    Department of Public Health, Yokohama City University School of Medicine, Yokohama, Japan; Emerging Infectious Diseases Research Center, Advanced Medical Research Center, Yokohama City University, Yokohama, Japan

    2 shared publications
  • Hideaki Kato

    Infection Prevention and Control Department, Yokohama City University Hospital, Yokohama, Japan; Emerging Infectious Diseases Research Center, Advanced Medical Research Center, Yokohama City University, Yokohama, Japan

    2 shared publications
  • Kaori Sano

    Influenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan

    2 shared publications
  • Kei Miyakawa

    Influenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.

    2 shared publications

Latest Publications

  • Neutralizing antibody evasion of SARS-CoV-2 JN.1 derivatives KP.3, KP.3.1.1, LB.1, and XEC

    by Kaori Sano, Kei Miyakawa, Hideaki Kato, Yayoi Kimura, Atsushi Goto, Akihide Ryo, Shinji Watanabe, Hideki Hasegawa


  • Open Access

    Multiple Respiratory Virus Detection in Acute Respiratory Infection Patients in Mie Prefecture, Japan, 2021–2023

    by Yuriko Tomita, Hiyori Okura, Rika Mochizuki, Manami Negoro, Takuya Yano, Yusuke Kobayashi, Ikuyo Takayama, Kiyosu Taniguchi, Shinji Watanabe, Hideki Hasegawa

    The Coronavirus disease 2019 (COVID-19) pandemic significantly impacted the circulation patterns of respiratory viruses worldwide. To better understand viral circulation patterns during the transition from pandemic to endemic phase, we conducted comprehensive respiratory virus surveillance in Mie Prefecture, Japan, during 2021–2023, coinciding with the Delta-to-Omicron transition of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). We collected respiratory specimens from acute respiratory infection patients in medical institutions, detecting 19 respiratory viruses using real-time PCR in 1573 valid samples out of 1605 specimens. Demographic and clinical data were available for some specimens. SARS-CoV-2 Omicron strains showed a peak positivity of 15–25% during the epidemic, while respiratory syncytial virus and human rhinovirus/enterovirus exhibited one to two annual epidemic peaks up to 57%, and human adenovirus maintained a positivity rate of 5–20% throughout the year. Age-dependent analysis revealed the significant detection of multiple viruses, particularly in children under 2 years, with up to six viruses detected simultaneously in those under 5 years. Our findings demonstrate varied respiratory virus prevalence patterns, with some viruses remaining active during the Omicron epidemic, suggesting its limited impact on other viruses. This comprehensive approach should enhance the understanding of respiratory virus epidemic dynamics and inform public health strategies.


  • Open Access

    Efficacy of an Inactivated Whole‐Virus A/Victoria/361/2011 (IVR‐165) (H3N2) Influenza Vaccine in Ferrets

    by Noriko Kishida, Masaki Imai, Akira Ainai, Hideki Asanuma, Reiko Saito, Seiichiro Fujisaki, Masayuki Shirakura, Kazuya Nakamura, Tomoko Kuwahara, Emi Takashita, et al.

    It has been reported that the high‐growth reassortant (HGR) A(H3N2) influenza viruses used for split influenza vaccine (SV) production have some amino acid substitutions in hemagglutinin due to egg adaptation during virus propagation, causing antigenic differences between HGR and epidemic viruses. To clarify whether inactivated whole‐virus vaccine (WV) derived from the A(H3N2) HGR virus possessing egg adaptation could induce cross‐protective immune responses against epidemic A(H3N2) viruses, the efficacy of WV was compared with that of SV in a ferret model. When the ferrets immunized with WV or SV derived from HGR A/Victoria/361/2011 (IVR‐165) virus were challenged with the homologous virus A/Victoria/361/2011 (IVR‐165) or its original cell‐propagated A/Victoria/361/2011 virus, respectively, WV successfully shortened the duration of virus shedding of both challenge viruses, whereas SV shortened only that of the homologous virus, A/Victoria/361/2011 (IVR‐165). When WV‐immunized ferrets were challenged with A/Fukushima/69/2015 virus, which is an epidemic virus antigenically different from the A/Victoria/361/2011 virus, WV could shorten the duration of shedding of this virus. In addition, we found that early induction of nasal IgG and IgA antibodies by vaccines helped shorten the virus‐shedding period, although this was dependent on the degree of difference in antigenicity of the challenge virus. These results indicate that vaccination with WV, not with SV, would be a solution to avoid decreased vaccine effectiveness due to the antigenic change of HGR virus by egg adaptation during virus propagation.


  • Open Access

    Neutralizing antibody evasion of SARS-CoV-2 JN.1 derivatives KP.3, KP.3.1.1, LB.1, and XEC

    by Kaori Sano, Kei Miyakawa, Hideaki Kato, Yayoi Kimura, Atsushi Goto, Akihide Ryo, Shinji Watanabe, Hideki Hasegawa

    The emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including XBB.1.5 monovalent vaccine. In COVID-19-naïve individuals, KP.3.1.1 and LB.1 showed substantial immune escape, while previously infected individuals maintained neutralization activity against all variants. We also demonstrated that JN.1-based immunization induces robust cross-neutralizing activity against emerging variants. A single amino acid deletion at position 31 in the spike protein significantly impacted immune evasion. These findings support the potential effectiveness of JN.1-based vaccines while highlighting the need for continued surveillance and vaccine optimization.


  • Open Access

    Antiviral Susceptibilities of Distinct Lineages of Influenza C and D Viruses

    by Emi Takashita, Shin Murakami, Yoko Matsuzaki, Seiichiro Fujisaki, Hiroko Morita, Shiho Nagata, Misa Katayama, Katsumi Mizuta, Hidekazu Nishimura, Shinji Watanabe, et al.

    The emergence and spread of antiviral-resistant influenza viruses are of great concern. To minimize the public health risk, it is important to monitor antiviral susceptibilities of influenza viruses. Analyses of the antiviral susceptibilities of influenza A and B viruses have been conducted globally; however, those of influenza C and D viruses are limited. Here, we determined the susceptibilities of influenza C viruses representing all six lineages (C/Taylor, C/Yamagata, C/Sao Paulo, C/Aichi, C/Kanagawa, and C/Mississippi) and influenza D viruses representing four lineages (D/OK, D/660, D/Yama2016, and D/Yama2019) to RNA polymerase inhibitors (baloxavir and favipiravir) by using a focus reduction assay. All viruses tested were susceptible to both drugs. We then performed a genetic analysis to check for amino acid substitutions associated with baloxavir and favipiravir resistance and found that none of the viruses tested possessed these substitutions. Use of the focus reduction assay with the genotypic assay has proven valuable for monitoring the antiviral susceptibilities of influenza C and D viruses as well as influenza A and B viruses. Antiviral susceptibility monitoring of all influenza virus types should continue in order to assess the public health risks posed by these viruses.


  • Open Access

    Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys

    by Masayuki Hashimoto, Noriyo Nagata, Tomoyuki Homma, Hiroki Maeda, Keiji Dohi, Naomi M. Seki, Ken Yoshihara, Naoko Iwata-Yoshikawa, Nozomi Shiwa-Sudo, Yusuke Sakai, et al.